These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36323434)

  • 41. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
    Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
    Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
    Mandl SJ; Rountree RB; Dela Cruz TB; Foy SP; Cote JJ; Gordon EJ; Trent E; Delcayre A; Franzusoff A
    J Immunother Cancer; 2014; 2(1):34. PubMed ID: 25328681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.
    Gómez CE; Perdiguero B; Cepeda MV; Mingorance L; García-Arriaza J; Vandermeeren A; Sorzano CÓ; Esteban M
    J Virol; 2013 Jul; 87(13):7282-300. PubMed ID: 23596307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
    Karan D
    Vaccine; 2017 Oct; 35(43):5794-5798. PubMed ID: 28939158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
    García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
    PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
    Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
    Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
    Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
    J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.
    Backes S; Jäger C; Dembek CJ; Kosinska AD; Bauer T; Stephan AS; Dišlers A; Mutwiri G; Busch DH; Babiuk LA; Gasteiger G; Protzer U
    Vaccine; 2016 Feb; 34(7):923-32. PubMed ID: 26776470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
    Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
    J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
    García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
    PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.
    Forbes EK; Biswas S; Collins KA; Gilbert SC; Hill AV; Draper SJ
    J Immunol; 2011 Oct; 187(7):3738-50. PubMed ID: 21876036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
    Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
    J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.
    Spencer AJ; Cottingham MG; Jenks JA; Longley RJ; Capone S; Colloca S; Folgori A; Cortese R; Nicosia A; Bregu M; Hill AV
    PLoS One; 2014; 9(6):e100538. PubMed ID: 24945248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
    Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
    Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
    Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
    PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination.
    Qiu J; Peng S; Ma Y; Yang A; Farmer E; Cheng MA; Roden RBS; Wu TC; Chang YN; Hung CF
    Virology; 2018 Dec; 525():205-215. PubMed ID: 30296681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
    García-Arriaza J; Nájera JL; Gómez CE; Sorzano CO; Esteban M
    PLoS One; 2010 Aug; 5(8):e12395. PubMed ID: 20811493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
    Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
    J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.
    Vuola JM; Keating S; Webster DP; Berthoud T; Dunachie S; Gilbert SC; Hill AV
    J Immunol; 2005 Jan; 174(1):449-55. PubMed ID: 15611270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
    Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
    J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.